538 related articles for article (PubMed ID: 9764397)
1. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
Felmingham D; Brown DF; Soussy CJ
Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin.
Grüneberg RN; Hryniewicz W
Int J Antimicrob Agents; 1998 Nov; 10(4):271-7. PubMed ID: 9916900
[TBL] [Abstract][Full Text] [Related]
3. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
[TBL] [Abstract][Full Text] [Related]
4. Proficiency of Italian clinical laboratories in detecting reduced glycopeptide susceptibility in Enterococcus and Staphylococcus spp. using routine laboratory methodologies.
Jones ME; Gesu G; Ortisi G; Sahm DF; Critchley IA; Goglio A;
Clin Microbiol Infect; 2002 Feb; 8(2):101-11. PubMed ID: 11952723
[TBL] [Abstract][Full Text] [Related]
5. Quality assessment of glycopeptide susceptibility tests: a European collaborative study. European Glycopeptide Resistance Group.
Brown DF; Courvalin P
Int J Antimicrob Agents; 1997 Jan; 9(3):153-63. PubMed ID: 9552711
[TBL] [Abstract][Full Text] [Related]
6. Avoparcin, a glycopeptide used in animal foods: antimicrobial spectrum and potency tested against human isolates from the United States.
Cormican MG; Erwin ME; Jones RN
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):241-8. PubMed ID: 9458981
[TBL] [Abstract][Full Text] [Related]
7. Glycopeptide resistance in Enterococcus spp. and coagulase-negative staphylococci from hospitalised patients in Germany: occurrence, characteristics and dalbavancin susceptibility.
Kresken M; Klare I; Wichelhaus TA; Wohlfarth E; Layer-Nicolaou F; Neumann B; Werner G;
J Glob Antimicrob Resist; 2022 Mar; 28():102-107. PubMed ID: 34958996
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides.
Del' Alamo L; Cereda RF; Tosin I; Miranda EA; Sader HS
Diagn Microbiol Infect Dis; 1999 Jul; 34(3):185-91. PubMed ID: 10403098
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
Jensen KT; Schønheyder H; Pers C; Thomsen VF
APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
[TBL] [Abstract][Full Text] [Related]
10. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
Harland S; Tebbs SE; Elliott TS
J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
[TBL] [Abstract][Full Text] [Related]
13. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Zweifel MJ; Wilkie SC; Rodriguez MJ; Thompson RC; Cooper RD
Antimicrob Agents Chemother; 1996 Sep; 40(9):2194-9. PubMed ID: 8878606
[TBL] [Abstract][Full Text] [Related]
14. [In vitro susceptibilities of clinical isolates of coagulase-negative staphylococci to glycopeptide antibiotics].
Kato D; Hanaki H; Cui L; Oguri T; Hiramatsu K
Jpn J Antibiot; 1998 Dec; 51(12):735-45. PubMed ID: 10077772
[TBL] [Abstract][Full Text] [Related]
15. Teicoplanin Chemistry and Microbiology.
Parenti F; Schito GC; Courvalin P
J Chemother; 2000 Nov; 12 Suppl 5():5-14. PubMed ID: 11131964
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of teicoplanin against gram-positive cocci.
Allouch P; Pina P; Chaplain C; Delarbre JM; Geffroy F; Grasmick CP; Marcolin M; Morel A; Pangon B; Rio Y; Sédaillan A
Pathol Biol (Paris); 2000 Oct; 48(8):792-5. PubMed ID: 11244609
[TBL] [Abstract][Full Text] [Related]
17. [Activity of vancomycin, teicoplanin and linezolid in methicillin resistant coagulase-negative Staphylococci isolates from paediatric blood cultures].
Fajardo Olivares M; Hidalgo Orozco R; Rodríguez Garrido S; Gaona Álvarez C; Sánchez Silos RM; Hernández Rastrollo R; Martínez Tallo E; Cordero Carrasco JL
Rev Esp Quimioter; 2012 Mar; 25(1):25-30. PubMed ID: 22488538
[TBL] [Abstract][Full Text] [Related]
18. Glycopeptide resistance in coagulase-negative staphylococci.
Biavasco F; Vignaroli C; Varaldo PE
Eur J Clin Microbiol Infect Dis; 2000 Jun; 19(6):403-17. PubMed ID: 10947214
[TBL] [Abstract][Full Text] [Related]
19. Glycopeptide susceptibility profiles of Staphylococcus haemolyticus bloodstream isolates.
Biavasco F; Vignaroli C; Lazzarini R; Varaldo PE
Antimicrob Agents Chemother; 2000 Nov; 44(11):3122-6. PubMed ID: 11036034
[TBL] [Abstract][Full Text] [Related]
20. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
Streit JM; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]